| Advisory Board Member | Title and Organization |
| Jerry Casey, MBA | Independent Consultant Former President and COO, Sekisui Diagnostics, LLC |
| Margaret Chu-Moyer, PhD | Executive Director of Researcha and Massachusetts Site Head, Amgen |
| Anthony J. Coyle, PhD | CEO, Pandion Therapeutics |
| Alan Crane, MBA | Venture Partner and Entrepreneur, Polaris Venture Partners |
| Skip Fleshman, MS | Partner, Asset Management Ventures |
| Sandra Glucksman, PhD | President and CEO, Cedilla Therapeutics |
| Keith Gottesdiener, MD | CEO, Rhythm Pharmaceuticals, Inc. |
| Michael Magliochetti, MBA, PhD | Operating Partner, Riverside Partners |
| Imran Nasrullah, MS, JD, CLP | Vice President, Head, Open Innovation Center, North America – East, Bayer |
| Simon Read, PhD | Chief Scientific Officer, Ra Pharma |
| Ken Rhodes, PhD | Chief Scientific Officer, Yumanity Therapeutics |
| Craig Sorensen, PhD | Independent Pharma Consultant Former Vice President, External Research and Innovation, Vertex Pharmaceuticals Inc. |
| Beverly Teicher, PhD | Chief, Molecular Pharmacology Branch, National Cancer Institute |
| Josh Tolkoff, MS Eng | Managing Director, Ironwood Capital Management; Accelerator Executive, CIMIT |
| Stacie Weninger, PhD | Executive Director, F-Prime Biomedical Research Initiative |